Intec Pharma (NASDAQ:NTEC) Lowered to Neutral at HC Wainwright

HC Wainwright lowered shares of Intec Pharma (NASDAQ:NTEC) from a buy rating to a neutral rating in a research note released on Wednesday morning, BenzingaRatingsTable reports.

A number of other research analysts also recently issued reports on NTEC. Oppenheimer downgraded shares of Intec Pharma from an outperform rating to a market perform rating in a research report on Monday, July 22nd. Maxim Group downgraded shares of Intec Pharma from a buy rating to a hold rating in a research report on Monday, July 22nd. Zacks Investment Research upgraded shares of Intec Pharma from a sell rating to a hold rating and set a $6.50 target price on the stock in a research report on Tuesday, May 7th. ValuEngine upgraded shares of Intec Pharma from a hold rating to a buy rating in a research report on Thursday, August 1st. Finally, LADENBURG THALM/SH SH downgraded shares of Intec Pharma from a buy rating to a neutral rating in a research report on Monday, July 22nd. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $12.17.

Shares of NASDAQ NTEC remained flat at $$0.46 during midday trading on Wednesday. 1,049,762 shares of the stock were exchanged, compared to its average volume of 2,678,923. The stock has a market cap of $15.94 million, a P/E ratio of -0.33 and a beta of 0.23. Intec Pharma has a 1 year low of $0.42 and a 1 year high of $9.25. The firm’s fifty day moving average is $2.61.

Intec Pharma (NASDAQ:NTEC) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.05. Analysts forecast that Intec Pharma will post -1 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in the stock. Knott David M lifted its position in shares of Intec Pharma by 2.5% during the 1st quarter. Knott David M now owns 290,434 shares of the biotechnology company’s stock valued at $2,129,000 after acquiring an additional 6,961 shares during the period. BlackRock Inc. acquired a new position in shares of Intec Pharma during the 4th quarter valued at $67,000. Marshall Wace North America L.P. acquired a new position in shares of Intec Pharma during the 1st quarter valued at $117,000. Delek Group Ltd. acquired a new position in shares of Intec Pharma during the 1st quarter valued at $154,000. Finally, Sigma Planning Corp bought a new stake in Intec Pharma during the 1st quarter valued at $183,000. Institutional investors own 35.26% of the company’s stock.

About Intec Pharma

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

See Also: What is a Lock-Up Period?

Analyst Recommendations for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.